Inactive Instrument

GeneThera, Inc. Stock price Other OTC

Equities

GTHR

US37185E3062

Biotechnology & Medical Research

Sales 2020 - Sales 2021 - Capitalization 997K
Net income 2020 - Net income 2021 -1M EV / Sales 2020 -
Net Debt 2020 812K Net Debt 2021 811K EV / Sales 2021 -
P/E ratio 2020
-0.37 x
P/E ratio 2021
-0.81 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 47.21%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 65 98-12-31
Members of the board TitleAgeSince
Director of Finance/CFO 65 98-12-31
Director/Board Member 62 18-04-01
Director/Board Member - 21-12-10
More insiders
GeneThera, Inc. is a biotechnology company. The Company is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The Company has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The Company has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.
More about the company
  1. Stock
  2. Equities
  3. Stock GeneThera, Inc.
  4. Stock GeneThera, Inc. - Other OTC